Qena university hospital, Qena faculty of medicine, Qina, Egypt - 02 Oct `24Vitiligo, New Treatment and Serum s100B

Vitiligo, New Treatment and Serum s100B

Official title: Serum s100B in Generalized Vitiligo and Its Relation to Oral Baricitinib, Narrow Band Ultraviolet (B) Therapy

Status: Recruiting now

Description:

vitiligo is an autoimmune depigmenting skin disorder characterized by milky white macules or patches, with 2% worldwide prevalence. Vitiligo has unexpected course that significantly influences on patient's quality of life and self-esteem. Multiple medications have been introduced for vitiligo treatment, in this study we work on one of systemic JAK inhibitors

Phases: Phase 2, Phase 3.

What is being studied: drugs — Baricitinib, oral mini pulse; radiation — Narrow Band UVB Treatment.

Who can take part: ages 10 Years to 75 Years, 50 participants planned.

Enrollment status: the registry has not updated this study since its planned completion date, so its current status is unclear. The study started 02 October 2024 and was due to finish 01 October 2025.

Contact: Eman A Osman, bachelor.

Source: ClinicalTrials.gov, NCT06768840 (https://clinicaltrials.gov/study/NCT06768840).

Start date: October 02, 2024

Completion date: October 01, 2025

Organizer: South Valley University

Contact: Eman A Osman, bachelor

Tel.: +20 1127052748

Email: em.ea01127@gmail.com

Link: https://clinicaltrials.gov/study/NCT06768840

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference Vitiligo, New Treatment and Serum s100B . By submitting you agree to our Privacy Policy.

FAQOther Questions